GeneDx Holdings Corp. (WGS)
NASDAQ: WGS · Real-Time Price · USD
95.83
-5.75 (-5.66%)
At close: Feb 21, 2025, 4:00 PM
93.00
-2.83 (-2.95%)
After-hours: Feb 21, 2025, 5:55 PM EST
GeneDx Holdings Revenue
In the year 2024, GeneDx Holdings had annual revenue of $305.45M with 50.79% growth. GeneDx Holdings had revenue of $95.64M in the quarter ending December 31, 2024, with 66.57% growth.
Revenue (ttm)
$305.45M
Revenue Growth
+50.79%
P/S Ratio
8.44
Revenue / Employee
$305,450
Employees
1,000
Market Cap
2.63B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
WGS News
- 23 hours ago - GeneDx Holdings Corp. (WGS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Accesswire
- 1 day ago - GeneDx Holdings Corp. (WGS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Accesswire
- 2 days ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating GeneDx Holdings Corp. (WGS) And Encourages Investors to Connect - Accesswire
- 2 days ago - Reviewing GeneDx Holdings: Exome Testing And EPIC Aura Integration Make It A GARP 'Buy' - Seeking Alpha
- 3 days ago - GeneDx Holdings Corp. (WGS) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Bronstein, Gewirtz & Grossman, LLC Encourages GeneDx Holdings Corp. (WGS) Stockholders to Inquire about Securities Investigation - Accesswire
- 4 days ago - GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025 - Business Wire
- 4 days ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against GeneDx Holdings Corp. (WGS) and Encourages Investors to Learn More About the Investigation - Accesswire